S
Spectre Bio engineers Bacterial-like Particles (BLiPs) by decoupling physical structure from biological replication, creating non-replicating microbial shells. These particles retain native pathogen-associated molecular patterns (PAMPs) to elicit strong immune responses without infection risk. The platform serves as programmable hardware for deploying custom antigens and therapeutics for prophylactic applications.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Spectre Bio develops Bacterial-Like Particles (BLiPs) by inactivating bacterial genomes while preserving essential cellular machinery. These genome-cleaved chassis serve as intrinsically safe, highly programmable platforms for synthetic biology applications. The company enables the deployment of custom genetic software for diagnostics, therapeutics, and environmental functions.